We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAnthera Pharmaceuticals Inc

Anthera Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
23894
Market Cap
0.00M

Momentum Score

…

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anthera Pharmaceuticals Inc is an OTC Pink-listed biotechnology company; publicly available information on its current operations, product pipeline and financial position is limited. Potential long-term growth drivers include advancing or licensing any remaining development-stage assets and strategic asset monetization, which may appeal to investors seeking speculative biotech upside.
Material investment risks include very limited disclosure, thin trading liquidity on the Pink market, potential absence of revenues, and high clinical, regulatory and financing uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-28.26M
Debt / Equity
-
ROE
-568.85%
Net Debt
-2.20M
ROCE
3509.83%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2017-12-31
Income before tax - - - - -26.87M
Minority interest - - - - 0.00M
Net income - - - - -16.93M
Selling general administrative - - - - 7.94M
Gross profit - - - - -28.49M
Reconciled depreciation - - - - 0.28M
Ebit - - - - -36.43M
Ebitda - - - - -46.19M
Depreciation and amortization 0.23M 0.24M 0.21M 0.17M -9.76M
Non operating income net other - - - - 9.56M
Operating income - - - - -36.43M
Other operating expenses - - - - 36.53M
Interest expense - - - - 0.00M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense - - - - -9.94M
Total revenue - - - - 0.00M
Total operating expenses - - - - 36.53M
Cost of revenue - - - - 28.49M
Total other income expense net - - - - 9.56M
Discontinued operations - - - - 0.00M
Net income from continuing ops - - - - -26.87M
Net income applicable to common shares - - - - -29.38M
Preferred stock and other adjustments - - - - 2.50M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2017-12-31
Total assets - - - - 3.67M
Intangible assets - - - - 0.00M
Other current assets - - - - 0.99M
Total liab - - - - 9.17M
Total stockholder equity - - - - -5.50M
Deferred long term liab - - - - 0.00M
Other current liab - - - - 2.88M
Common stock - - - - 0.01M
Retained earnings - - - - -434.43M
Other liab - - - - 4.46M
Good will - - - - 0.00M
Other assets - - - - 0.00M
Cash - - - - 2.20M
Total current liabilities - - - - 4.71M
Net debt - - - - -2.20M
Short term debt - - - - 0.00M
Short long term debt - - - - 0.00M
Other stockholder equity - - - - 428.60M
Property plant equipment - - - - 0.48M
Total current assets - - - - 3.19M
Long term investments - - - - 0.00M
Net tangible assets - - - - -5.83M
Short term investments - - - - 0.00M
Long term debt - - - - 0.00M
Inventory - - - - 0.00M
Accounts payable - - - - 1.83M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income - - - - 0.00M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - - 0.00M
Preferred stock total equity - - - - 0.33M
Retained earnings total equity - - - - -434.43M
Treasury stock - - - - 0.00M
Non currrent assets other - - - - 0.00M
Non current assets total - - - - 0.48M
Breakdown 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31
Type yearly yearly yearly yearly yearly
Date 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31
Investments 0.00M -0.77M 0.00M 0.00M 5.33M
Change to liabilities -2.95M -0.61M 0.46M -1.21M -5.80M
Total cashflows from investing activities -0.92M -0.77M -0.08M 10.00M -4.69M
Net borrowings 0.00M 0.00M 0.00M -18.09M -2.64M
Total cash from financing activities 18.25M 23.58M 75.30M -7.71M 43.12M
Change to operating activities -2.09M 1.63M 0.35M 1.25M -
Net income -26.87M -55.52M -35.22M -29.60M -30.86M
Change in cash -18.65M -26.11M 44.31M -23.31M 6.51M
Begin period cash flow 20.84M 46.95M 2.64M 25.95M 19.43M
End period cash flow 2.20M 20.84M 46.95M 2.64M 25.95M
Total cash from operating activities -36.90M -48.92M -30.91M -25.60M -31.91M
Depreciation 0.28M 0.27M 0.28M 0.34M 0.35M
Other cashflows from investing activities 0.00M 0.00M 0.00M 10.00M -10.00M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory 0.00M 1.63M 0.35M 0.00M 0.00M
Change to account receivables -0.39M 0.33M -0.33M -0.33M 0.00M
Sale purchase of stock 0.27M 6.72M 75.30M 10.39M -0.00M
Other cashflows from financing activities 0.02M 16.84M 0.08M 0.01M 19.77M
Change to netincome -5.26M 5.00M 3.54M 3.17M 3.16M
Capital expenditures 0.92M 0.77M 0.08M 0.08M 0.01M
Change receivables - 0.33M -0.33M - -
Cash flows other operating -9.37M -3.02M -0.20M -0.03M 0.07M
Exchange rate changes - - - - -0.00M
Cash and cash equivalents changes -18.65M -26.11M 44.31M -23.31M 6.51M
Change in working capital -5.04M 1.34M 0.49M 0.04M -5.73M
Stock based compensation 4.38M 6.74M 3.54M 2.17M 3.15M
Other non cash items -9.64M -1.74M 3.54M 1.00M 4.31M
Free cash flow -36.90M -49.69M -30.99M -25.60M -31.93M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ANTH
Anthera Pharmaceuticals Inc		 -
-%		 0.00 - - - 0.11 0.21
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Anthera Pharmaceuticals Inc

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

The Pennzoil Building, Houston, TX, United States, 77002

410 350 1839

https://www.anthera.com

21

Name Title Year Born
Mr. Paul F. Truex M.B.A., MBA Exec. Chairman 1969
Mr. John Craig Thompson CEO & Director 1967
Ms. May Liu Sr. VP of Fin. & Admin. and Principal Accounting Officer 1976
Dr. Paul Adams Ph.D. Sr. VP of Global Regulatory Affairs and Compliance 1963
Joshua Caldwell Chief Liquidating Officer NA
Mr. Bradley A. Bugdanowitz Esq. Sec. NA
Ms. Klara A. Dickinson-Eason Advisor 1968
Dr. Charles V. Olson D.Sc. Advisor 1957
Mr. Paul F. Truex M.B.A. Executive Chairman 1969
Ms. May Liu CPA Senior VP of Finance & Administration and Principal Accounting Officer 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…